EO2463 for Follicular Lymphoma

Dana Farber Cancer Institute, Boston, MA
Follicular Lymphoma+1 More ConditionsEO2463 - Biological
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new drug, EO2463, to see if it is safe and effective in treating patients with indolent non-Hodgkin's lymphoma.

Eligible Conditions
  • Follicular Lymphoma
  • Marginal Zone Lymphoma

Treatment Effectiveness

Phase-Based Effectiveness

1 of 3
Phase 1 & 2

Similar Trials

1
Copanlisib
1
Oral Azacitidine
1
Gemcitabine Hydrochloride

Study Objectives

2 Primary · 5 Secondary · Reporting Duration: Up to 7 years after last patient enrolled

Up to 24 months
Assessment of the Immunogenicity in Relation to OMP72, OMP64, OMP65, OMP66, and UCP2 that Compose EO2463
Overall Response Rate
Phase 1: Recommended Phase 2 Dose | Adverse Events Assessment |
Phase 2: Overall Response Rate
Safety and Tolerability for EO2463 Administered as Monotherapy and in Combination with Lenalidomide, Rituximab and Lenalidomide/Rituximab
Year 7
Duration of response
Evaluation of Overall Survival

Trial Safety

Phase-Based Safety

1 of 3

Similar Trials

1
Copanlisib
1
Oral Azacitidine
1
Gemcitabine Hydrochloride

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 10 Other Conditions
This treatment demonstrated efficacy for 10 other conditions.
No Placebo Group
All patients enrolled in this trial will receive the new treatment.

Trial Design

4 Treatment Groups

Cohort 2
1 of 4
Cohort 3
1 of 4
Cohort 4
1 of 4
Cohort 1
1 of 4

Experimental Treatment

60 Total Participants · 4 Treatment Groups

Primary Treatment: EO2463 · No Placebo Group · Phase 1 & 2

Cohort 2
Biological
Experimental Group · 1 Intervention: EO2463 · Intervention Types: Biological
Cohort 3Experimental Group · 2 Interventions: EO2463, rituximab · Intervention Types: Biological, Biological
Cohort 4Experimental Group · 3 Interventions: EO2463, lenalidomide, rituximab · Intervention Types: Biological, Drug, Biological
Cohort 1Experimental Group · 3 Interventions: EO2463, lenalidomide, rituximab · Intervention Types: Biological, Drug, Biological
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Lenalidomide
FDA approved
Rituximab
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 7 years after last patient enrolled

Who is running the clinical trial?

EnteromeLead Sponsor
8 Previous Clinical Trials
576 Total Patients Enrolled
Jan Fagerberg, MDStudy DirectorEnterome
1 Previous Clinical Trials
34 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 0 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
References

Frequently Asked Questions

How many participants have signed up for the research thus far?

"This clinical trial requires 60 individuals meeting the necessary eligibility criteria. Patients may enroll out of either University of Rochester Medical Center (URMC) - Wilmot Cancer Institute (WCI) in Rochester, NY or Dana Farber Cancer Institute located in Boston, MA." - Anonymous Online Contributor

Unverified Answer

Is entry into this experiment open to prospective participants?

"Yes indeed. According to information held on clinicaltrials.gov, this trial initiated recruitment June 5th 2021 and is actively seeking out participants as recently as July 26th 2022. The team seeks 60 volunteers across 4 medical sites." - Anonymous Online Contributor

Unverified Answer

Has EO2463 yielded any noteworthy outcomes in prior research?

"Initially, EO2463 was studied in 1993 at the National Institutes of Health Clinical Centre on Rockville Pike. Since then there have been 1105 completed studies and 609 ongoing trials--many of which are being conducted in Rochester, New York." - Anonymous Online Contributor

Unverified Answer

To which ailments is EO2463 commonly administered?

"EO2463 is often prescribed to treat diffuse large b-cell lymphoma (dlbcl). Additionally, there may be some efficacy in treating conditions such as prior systemic chemotherapy regimens, B-cell lymphomas and polyangium." - Anonymous Online Contributor

Unverified Answer

What is the primary objective of this clinical research?

"This trial will assess the efficacy of this medication over a 24 month period, with its primary outcome being Phase 1: Recommended Phase 2 Dose | Adverse Events Assessment. Additionally, researchers will be recording Secondary Outcomes such as Overall Response Rate and Safety & Tolerability for EO2463 Administered Monotherapy or in Combination with Lenalidomide/Rituximab. Lastly, the Duration of Response is also documented by both Lugano Classification 2014 and Lymphoma Response to Immunomodulatory Therapy Criteria (Lyric) 2016 standards." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top